Madrigal Pharmaceuticals Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Madrigal Pharmaceuticals stock.
View analyst ratings for Madrigal Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Madrigal Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Madrigal Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Madrigal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) released its quarterly earnings results on Thursday, May, 6th. The biopharmaceutical company reported ($3.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.85) by $0.53.
View Madrigal Pharmaceuticals' earnings history.

Madrigal Pharmaceuticals' stock was trading at $81.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MDGL stock has increased by 63.5% and is now trading at $132.53.
View which stocks have been most impacted by COVID-19.

10 analysts have issued 12 month price targets for Madrigal Pharmaceuticals' stock. Their forecasts range from $114.00 to $204.00. On average, they anticipate Madrigal Pharmaceuticals' stock price to reach $167.60 in the next year. This suggests a possible upside of 26.5% from the stock's current price.
View analysts' price targets for Madrigal Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Madrigal Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), United Therapeutics (UTHR) and Neurocrine Biosciences (NBIX).
View all of MDGL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Advaxis (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild).

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

Madrigal Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.80%), Artisan Partners Limited Partnership (1.30%), L1 Capital Pty Ltd (0.68%), Rafferty Asset Management LLC (0.17%), Swiss National Bank (0.14%) and Cambridge Investment Research Advisors Inc. (0.10%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc and Fred B Craves.
View institutional ownership trends for Madrigal Pharmaceuticals.

MDGL stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Los Angeles Capital Management LLC, Shikiar Asset Management Inc., Rhumbline Advisers, L1 Capital Pty Ltd, State Board of Administration of Florida Retirement System, Strs Ohio, and Pacer Advisors Inc.. Company insiders that have sold Madrigal Pharmaceuticals company stock in the last year include Bay City Capital Llc, and Fred B Craves.
View insider buying and selling activity for Madrigal Pharmaceuticals or view top insider-selling stocks.

MDGL stock was bought by a variety of institutional investors in the last quarter, including Rafferty Asset Management LLC, Assenagon Asset Management S.A., UBS Group AG, BlackRock Inc., DekaBank Deutsche Girozentrale, Artisan Partners Limited Partnership, JPMorgan Chase & Co., and E Fund Management Co. Ltd..
View insider buying and selling activity for Madrigal Pharmaceuticals or or view top insider-buying stocks.

Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MDGL stock can currently be purchased for approximately $132.53.

Madrigal Pharmaceuticals has a market capitalization of $2.20 billion. The biopharmaceutical company earns $-83,950,000.00 in net income (profit) each year or ($5.45) on an earnings per share basis.

Madrigal Pharmaceuticals employs 42 workers across the globe.

The official website for Madrigal Pharmaceuticals is www.madrigalpharma.com.

Madrigal Pharmaceuticals is headquartered at 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428.

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at (484) 380-9263 or via email at [email protected]